Olgu Sunumu

Paradoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report

Cilt: 43 Sayı: 2 1 Temmuz 2021
Cumhuriyet Tıp Dergisi Kapak
Cumhuriyet Tıp Dergisi
PDF İndir
EN

Paradoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report

Abstract

Anti-tumor necrosis factor agents are effective drugs for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Although it is indicated for the treatment of Ankylosing Spondylitis, there are recent publications about paradoxical side effects due to these agents, mostly in the form of case reports. In this article, we present the psoriasis case that develops paradoxically in a patient with ankylosing spondylitis using adalimumab.

Keywords

Kaynakça

  1. 1.Esener, Sarenur, ve İnci Mevlitoğlu. “Pustular bakterid of Andrews during infiliximab therapy for ankylosing spondylitis: A case report”. TURKDERM 48, sy S2 (15 Haziran 2014): 105-7. https://doi.org/10.4274/turkderm.48.s27
  2. 2. İpek, Serkan, Cem Çekiç, Emrah Alper, Zehra Akpınar, Hakan Çamyar, Mustafa Kartal, ve Belkıs Ünsal. “Ankilozan spondilit nedeniyle adalimumab kullanan bir hastada paradoksal olarak gelişen Crohn hastalığı”, t.y., 4.
  3. 3. Koyun, Bilgesu, Eda Özalp, Oğuzhan Acet, ve Oytun Erbaş. “Romatolojik ve otoimmün hastalıklarda interlökin 23/tip 17 yardımcı T hücreleri yolağı için etkili güncel tedavi yöntemleri”. Demiroğlu Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi 3, sy 1 (2018): 025-030. https://doi.org/10.5606/fng.transplantasyon.2018.007.
  4. 4. Böyük, Emine, Işıl Bulur, Zeynep Nurhan Saraçoğlu, Hilal Kaya Erdoğan, Deniz Arık. “Romatoid Artrit Tanısı ile Golimumab Tedavisi Alan Hastada Gelişen Palmoplantar Püstülozis”. http://www.dermatoz.org/archives/archive-detail/article-preview/romatoid-artrit-tans-ile-golimumab-tedavisi-alan-h/36602 (06 Ekim 2020)
  5. 5. Pugliese, D., L. Guidi, P. M. Ferraro, M. Marzo, C. Felice, L. Celleno, R. Landi, vd. “Paradoxical Psoriasis in a Large Cohort of Patients with Inflammatory Bowel Disease Receiving Treatment with Anti-TNF Alpha: 5-Year Follow-up Study”. Alimentary Pharmacology & Therapeutics 42, sy 7 (Ekim 2015): 880-88. https://doi.org/10.1111/apt.13352.
  6. 6. Soto Lopes, Marien Siqueira, Beatriz Moritz Trope, Maria Paula Rua Rochedo Rodriguez, Rachel Lima Grynszpan, Tullia Cuzzi, ve Marcia Ramos-E-Silva. “Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa”. Case Reports in Dermatology 5, sy 3 (2013): 326-31. https://doi.org/10.1159/000350930.
  7. 7. Sarpel, Tunay, Sibel Basaran, Filiz Dogan Akcam, Suhan Gunasti, ve Yasargul Denli. “Psoriasis Induced by Tumor Necrosis Factor-Alpha Antagonist Therapy: Case Series and Literature Overview”. Turkish Journal of Rheumatology 25, sy 2 (01 Haziran 2010): 91-94. https://doi.org/10.5152/tjr.2010.09.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Olgu Sunumu

Yazarlar

Sena İrkin
0000-0002-7840-2451
Türkiye

Burak Karakaş
0000-0003-3624-4958
Türkiye

Beliz Karataş
Türkiye

Yayımlanma Tarihi

1 Temmuz 2021

Gönderilme Tarihi

18 Aralık 2020

Kabul Tarihi

30 Haziran 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 43 Sayı: 2

DOI

https://doi.org/10.7197/cmj.842870

IZ

https://izlik.org/JA37NM28ME

Kaynak Göster

RIS / Bibtex
AMA
1.İrkin S, Çabuk Çelik N, Karakaş B, Karataş B, Şahin A. Paradoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report. CMJ. 2021;43(2):177-181. doi:10.7197/cmj.842870

Cited By

Paradoxical Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment

Cureus

https://doi.org/10.7759/cureus.42791